Implications of a RAD54L polymorphism (2290C/T) in human meningiomas as a risk factor and/or a genetic marker

BMC Cancer

Table 2 Heterozygotes and T-allele frequencies in population controls and meningioma patients. Alleles were identified by exon 18 PCR amplification followed by SSCP as described [12].

Groups and number of patients or tumour samples	Heterozygosis frequency^a	Group comparison for heterozygotes vs. homozygotes^b	T-allele frequency^c	Group comparison for T-allele frequency^b
A) Control blood from Ecuador N = 149	29/149 (0.195)		31/298 (0.104)
B) Control blood from Spain N = 87	15/87 (0.172)	A-B) OR = 1.160 (0.583 – 2.309) P = 0.7313	19/174 (0.109)	A-B) OR = 0.878 (0.5175 – 1.734) P = 0.8776
C) Patients blood from Spain^d N = 22	11/22 (0.500)	C-B) OR = 4.800 (1.758 – 13.103) P = 0.0036	13/44 (0.295)	C-B) OR = 3.421 (1.531 – 7.646) P = 0.0037
D) Meningioma tumours from Spain^d,e N = 29	2/29 (0.069)	D-B) OR = 0.355 (0.076 – 1.660) P = 0.2327	11/49 (0.224)	D-B) OR = 2.357 (1.081 – 5.140) P = 0.0455
E) Meningioma tumours from Ecuador^f N = 41	30/41 (0.732)	E-A) OR = 11.285 (5.064 – 25.148) P < 0.0001	30/82 (0.366)	E-A) OR = 4.969 (2.773 – 8.905) P = 0.0001

^a Number of heterozygotes / number of cases or tumour samples. Frequency in brackets. ^b Odds Ratio (OR) with 95% confidence values in brackets and P value (two-sided Fisher's exact test) ^c Number of T-alleles / total chromosomes in group. Frequency in brackets. ^d Patients selected for LOH in 1p markers in tumour samples. Blood was unavailable in 7 of the patients. Data revised from Mendiola et al. 1999 (ref. 12)^e Number of chromosomes is reduced to 49 for LOH found in 9 samples. ^f Archival paraffin samples as described in the methods. Hemizygosis was not evaluable due to lack of patients' blood.

ISSN: 1471-2407